Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 1.00 |
| ▸ | PGK1 | P00558 | 1/20 | 0.77 |
| ▸ | PGK2 | P07205 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758941 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL4803033 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL27578766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14853634 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL18464461 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL14928752 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL21276447 | 0.92 | ADORA3 (0.86) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL22224967 | 0.91 | ADORA3 (0.84) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL23760829 | 0.90 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 | |
| SCHEMBL20724628 | 0.90 | ADORA3 (0.82) | ADORA3ADORA1PGK1PGK2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | claimed |
| EP-4499824-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | claimed |
| US-20220306678-A1 | IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM | ARCTURUS THERAPEUTICS, INC. | 2022-09-29 | — | — | US | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | claimed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| US-20250382584-A1 | CELL | Tanabe, Koji (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4580609-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | disclosed |
| WO-2025104494-A2 | COMPOSITIONS AND METHODS FOR MODULATING PROTEIN INTERACTIONS | VERSAMEB AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA3 102/4885ADORA1 197/4885PGK1 1287/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA3 102/4885ADORA1 197/4885PGK1 1287/4885 |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | RNGTT, POLRMT, POLN | ADORA3 1331/4885ADORA1 2763/4885PGK1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.